AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 580214 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol (Tramal)
Number of subjects: 60
Study 580214 — intervention group
Group type: EXPERIMENTAL
Intervention: dextropropoxyphene
Number of subjects: 60
Study 580214 — intervention group
Group type: EXPERIMENTAL
Intervention: commercial drug mixture (acetylsalicylic acid 200 mg; phenacetin 200 mg; codeine phosphor. 10 mg; caffeine anhydr. 50 mg; phenobarbital 25 mg)
Number of subjects: 60
Study 31157983 — intervention group
Group type: EXPERIMENTAL
Intervention: CHANGE Asthma app
Number of subjects: 40
Study 31157983 — intervention group
Group type: COMPARATOR
Intervention: Control group (no app)
Number of subjects: 40
Study 29380610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound enamel preparation
Number of subjects: 60
Study 29380610 — intervention group
Group type: COMPARATOR
Intervention: Conventional diamond bur preparation
Number of subjects: 60
Study 26181254 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) alone
Number of subjects: 88
Study 26181254 — intervention group
Group type: COMPARATOR
Intervention: Whole-brain radiotherapy (WBRT) + SRS
Number of subjects: 88
Study 23928630 — intervention group
Group type: EXPERIMENTAL
Intervention: Video accompanied by a written leaflet
Number of subjects: 90
Study 23928630 — intervention group
Group type: COMPARATOR
Intervention: Leaflet alone
Number of subjects: 90
Study 23928630 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 90
Study 21665136 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) for 12 weeks
Number of subjects: 19
Study 21665136 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial support therapy (PST) control
Number of subjects: 19
Study 21665136 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC)
Number of subjects: 19
Study 19803365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavine (10 mL per 24 hours, for 5 days)
Number of subjects: 0
Study 19803365 — intervention group
Group type: COMPARATOR
Intervention: Standard antituberculosis therapy (placebo control)
Number of subjects: 0
Study 16959692 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat treatment for 6 months
Number of subjects: 27
Study 16959692 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonobese females)
Number of subjects: 27
Study 14762779 — intervention group
Group type: EXPERIMENTAL
Intervention: sulindac
Number of subjects: 41
Study 14762779 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study 11315893 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical GTN (10 mg)
Number of subjects: 80
Study 11315893 — intervention group
Group type: COMPARATOR
Intervention: Topical saline
Number of subjects: 80
Study 11315893 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ISDN (10 mg)
Number of subjects: 80
Study 11315893 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical GTN
Number of subjects: 80
Study 11315893 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ISDN
Number of subjects: 80
Study 9160362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile pump flow
Number of subjects: 0
Study 9160362 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile pump flow
Number of subjects: 0
Study 8214791 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid etching
Number of subjects: 600
Study 8214791 — intervention group
Group type: COMPARATOR
Intervention: 2% phosphoric acid etching
Number of subjects: 600
Study 3568581 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade (2 X 80 mg oral propranolol)
Number of subjects: 16
Study 3568581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29735237 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity physical activity (≥150 minutes/week)
Number of subjects: 147
Study 29735237 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity physical activity
Number of subjects: 147
Study 29735237 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-high intensity physical activity
Number of subjects: 147
Study 27108821 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (2.5g intravenous, 5min before tourniquet release)
Number of subjects: 62
Study 27108821 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 62
Study 24015935 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (350 mg Mg d(‐1), 4 weeks)
Number of subjects: 25
Study 24015935 — intervention group
Group type: COMPARATOR
Intervention: Control group (500 mg maltodextrin d(‐1), 4 weeks)
Number of subjects: 25
Study 23541623 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg of EV71 antigen with 150 μg of adjuvant (Group A05)
Number of subjects: 60
Study 23541623 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg of EV71 antigen with 300 μg of adjuvant (Group B10)
Number of subjects: 60
Study 20734365 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR (50-300 mg/day)
Number of subjects: 776
Study 20734365 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR
Number of subjects: 776
Study 20734365 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 776
Study 18439112 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 19
Study 18439112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 15992232 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of ear temperature bilaterally using an infrared tympanic thermometer (ITT)
Number of subjects: 132
Study 12742289 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists (CAs)
Number of subjects: 3327
Study 12742289 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dihydropyridines
Number of subjects: 3327
Study 10370667 — intervention group
Group type: EXPERIMENTAL
Intervention: 6MU IFN-alpha 2a t.i.w. for 3 months followed by 3MU t.i.w. for another 3 months (group A)
Number of subjects: 63
Study 10370667 — intervention group
Group type: EXPERIMENTAL
Intervention: 3MU IFN-alpha 2a t.i.w. for 6 months (group B)
Number of subjects: 63
Study 8668894 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose i.v. methylprednisolone
Number of subjects: 0
Study 8668894 — intervention group
Group type: COMPARATOR
Intervention: Oral steroids (1 mg per kilogram of body weight per day)
Number of subjects: 0
Study 2067345 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaferon (alpha 2‐interferon)
Number of subjects: 0
Study 2067345 — intervention group
Group type: COMPARATOR
Intervention: Prodigiosan plus ibuprofen
Number of subjects: 0
Study 6409456 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting met-enkephalin analogue DAMME
Number of subjects: 6
Study 6409456 — intervention group
Group type: COMPARATOR
Intervention: Cholinergic antagonist, pirenzepine
Number of subjects: 6
Study 31347010 — intervention group
Group type: EXPERIMENTAL
Intervention: ConquerFear intervention
Number of subjects: 152
Study 31347010 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training (control)
Number of subjects: 152
Study 29985775 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-based supplement containing 1546 mg of omega-3 polyunsaturated fatty acid (551 mg EPA and 551 mg DHA) twice daily (FO)
Number of subjects: 20
Study 29985775 — intervention group
Group type: COMPARATOR
Intervention: Protein-based placebo (P)
Number of subjects: 20
Study 29985775 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-based supplement containing 1546 mg of omega-3 polyunsaturated fatty acid (FO)
Number of subjects: 20
Study 26370224 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilayer technique protected with petroleum jelly (PJ)
Number of subjects: 208
Study 26370224 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional GIC insertion protected with nano‐filled particles coating (NPC)
Number of subjects: 208
Study 26370224 — intervention group
Group type: COMPARATOR
Intervention: Conventional GIC insertion protected with petroleum jelly (PJ)
Number of subjects: 208
Study 24354307 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 0
Study 24354307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22560253 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling by nurse practitioner (NP) for three years
Number of subjects: 457
Study 22560253 — intervention group
Group type: COMPARATOR
Intervention: Usual care by general practitioner (GP) with one consultation
Number of subjects: 457
Study 19958042 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (0.25 mg twice daily for 6 weeks, then 0.5 mg twice daily for 6 weeks)
Number of subjects: 14
Study 17293206 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing (AOP) at 50 beats/min greater than the mean nocturnal heart rate
Number of subjects: 14
Study 17293206 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing (AOP) at 20 beats/min greater than the mean nocturnal heart rate
Number of subjects: 14
Study 17293206 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing (AOP) at 10 beats/min greater than the mean nocturnal heart rate
Number of subjects: 14
Study 17293206 — intervention group
Group type: COMPARATOR
Intervention: Control studies
Number of subjects: 14
Study 15385341 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol plus enoximone (initial bolus of 0.5 mg/kg followed by a continuous infusion of 2.5 microg x kg(‐1) x min(‐1))
Number of subjects: 42
Study 15385341 — intervention group
Group type: COMPARATOR
Intervention: Saline solution as placebo (control)
Number of subjects: 42
Study 12506821 — intervention group
Group type: EXPERIMENTAL
Intervention: Puréed food texture
Number of subjects: 3
Study 12506821 — intervention group
Group type: EXPERIMENTAL
Intervention: Minced food texture
Number of subjects: 3
Study 12506821 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft food texture
Number of subjects: 3
Study 9561866 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine penicillin
Number of subjects: 42
Study 9561866 — intervention group
Group type: COMPARATOR
Intervention: Sulbactam-ampicillin
Number of subjects: 42
Study 7855784 — intervention group
Group type: EXPERIMENTAL
Intervention: High-purity factor VIII concentrate (HP-F VIII)
Number of subjects: 36
Study 7855784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-pure factor VIII product (UP-F VIII)
Number of subjects: 36
Study 2670395 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at 0.5 microgram/min
Number of subjects: 0
Study 2670395 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at 3 microgram/min
Number of subjects: 0
Study 2670395 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion at 0.5 microgram/min
Number of subjects: 0
Study 2670395 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion at 3 microgram/min
Number of subjects: 0
Study 2670395 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0
Study 2670395 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at 6 microgram/min
Number of subjects: 0
Study 2670395 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion at 6 microgram/min
Number of subjects: 0
Study 2670395 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic, euglycaemic glucose clamp
Number of subjects: 0
Study 824068 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled BRL 10833, dosage: 40 mg
Number of subjects: 10
Study 31286906 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief structured intervention (n = 107)
Number of subjects: 261
Study 31286906 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 117)
Number of subjects: 261
Study 31286906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 261
Study 28637708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydration (HYP) - induced by 2.5% body mass loss
Number of subjects: 7
Study 28637708 — intervention group
Group type: COMPARATOR
Intervention: Euhydration (EU) - replaced sweat loss
Number of subjects: 7
Study 28637708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypohydration (HYP)
Number of subjects: 7
Study 28637708 — intervention group
Group type: COMPARATOR
Intervention: Euhydration (EU)
Number of subjects: 7
Study 25837247 — intervention group
Group type: EXPERIMENTAL
Intervention: VbX warm‐up (VbX‐WU)
Number of subjects: 12
Study 25837247 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural activation warm‐up (Neu‐WU)
Number of subjects: 12
Study 25837247 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic warm‐up (Dyn‐WU)
Number of subjects: 12
Study 25837247 — intervention group
Group type: COMPARATOR
Intervention: Control (No VbX)
Number of subjects: 12
Study 23439063 — intervention group
Group type: EXPERIMENTAL
Intervention: PC‐DC injections
Number of subjects: 13
Study 23439063 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 13
Study 20816037 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 44
Study 17869451 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐RT(90‐01)
Number of subjects: 302
Study 17869451 — intervention group
Group type: COMPARATOR
Intervention: CT‐RT(SC(C/F))
Number of subjects: 302
Study 17869451 — intervention group
Group type: COMPARATOR
Intervention: CT‐RT(SC(WC))
Number of subjects: 302
Study 17869451 — intervention group
Group type: EXPERIMENTAL
Intervention: C/F chemotherapy, cisplatin dose >or=200 mg/m(2), Stage I‐II disease, negative pelvic lymph nodes
Number of subjects: 302
Study 17112689 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDCAP
Number of subjects: 25
Study 17112689 — intervention group
Group type: COMPARATOR
Intervention: Conventional neonatal care
Number of subjects: 25
Study 15319332 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of [(14)C]tesaglitazar (intravenous)
Number of subjects: 8
Study 15319332 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of nonlabeled tesaglitazar (oral)
Number of subjects: 8
Study 11341460 — intervention group
Group type: EXPERIMENTAL
Intervention: Betula 30c
Number of subjects: 51
Study 11341460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 9481614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg
Number of subjects: 14
Study 9481614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg
Number of subjects: 14
Study 9481614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 14
Study 7940139 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile ocular blood flow (POBF) measurement in NTG patients
Number of subjects: 10
Study 7940139 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study 2908715 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0
Study 2908715 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 0
Study 2908715 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 31267162 — intervention group
Group type: EXPERIMENTAL
Intervention: Postfracture notification program
Number of subjects: 18541
Study 31267162 — intervention group
Group type: COMPARATOR
Intervention: Control group (without a MOF; N = 92,705)
Number of subjects: 18541
Study 28544892 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic expression of emotions
Number of subjects: 97
Study 28544892 — intervention group
Group type: COMPARATOR
Intervention: Static images of realistic human faces
Number of subjects: 97
Study 28544892 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood-induction (positive or negative)
Number of subjects: 97
Study 28544892 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial-to-trial bias estimations
Number of subjects: 97
Study 26152126 — intervention group
Group type: EXPERIMENTAL
Intervention: High-saturated fatty acid (HSFA) diet
Number of subjects: 24
Study 26152126 — intervention group
Group type: COMPARATOR
Intervention: High-monounsaturated fatty acid (HMUFA) diet
Number of subjects: 24
Study 26152126 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-complex carbohydrate diet supplemented with placebo (LFHCC)
Number of subjects: 24
Study 26152126 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-complex carbohydrate diet supplemented with long chain n-3 polyunsaturated fatty acids (LFHCC n-3)
Number of subjects: 24
Study 23117050 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological nursing intervention
Number of subjects: 86
Study 23117050 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 86
Study 21983400 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit from Smiling Hospital artists
Number of subjects: 24
Study 21983400 — intervention group
Group type: COMPARATOR
Intervention: Control group (no visit from artists)
Number of subjects: 24
Study 19230168 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies used by clinicians to facilitate decision making during randomization.
Number of subjects: 9
Study 19230168 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians' motivation for randomizing patients.
Number of subjects: 9
Study 19230168 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular meetings with the study group.
Number of subjects: 9
Study 19230168 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' attitudes towards randomization.
Number of subjects: 9
Study 16585808 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder postcard
Number of subjects: 49605
Study 16585808 — intervention group
Group type: EXPERIMENTAL
Intervention: Thank you postcard
Number of subjects: 49605
Study 16585808 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postcard)
Number of subjects: 49605
Study 12566871 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.125%
Number of subjects: 64
Study 12566871 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine 1.0%
Number of subjects: 64
Study 12566871 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 64
Study 12566871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 10866352 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled procedure with constant reinforcer ratio
Number of subjects: 8
Study 10866352 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled procedure with variable reinforcer ratio
Number of subjects: 8
Study 8627032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol
Number of subjects: 38
Study 8627032 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 38
Study 8627032 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine
Number of subjects: 38
Study 8627032 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocultivation with macrophages
Number of subjects: 38
Study 1419616 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 4044343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic external beam radiation (4000 rad) plus intraperitoneal radioactive chromic phosphate (10-20 millicuries)
Number of subjects: 53
Study 4044343 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 patients who did not receive chromic phosphate)
Number of subjects: 53
Study 31167870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) for 12 weeks
Number of subjects: 0
Study 31167870 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol (THC) as an open label add-on for primary CBD non-responders
Number of subjects: 0
Study 31167870 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 0
Study 30283981 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram
Number of subjects: 64
Study 30283981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 27549590 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Physical Activity (SPA) - 2 sessions per week for 20 weeks
Number of subjects: 56
Study 27549590 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressively Autonomous Physical Activity (PAPA) - 10 weeks of SPA followed by 10 weeks with one supervised session replaced by habit formation strategy
Number of subjects: 56
Study 24102348 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral liarozole 75 mg
Number of subjects: 64
Study 24102348 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral liarozole 150 mg
Number of subjects: 64
Study 24102348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 24102348 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral liarozole (both doses)
Number of subjects: 64
Study 22609619 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute dose of levodopa
Number of subjects: 55
Study 20417063 — intervention group
Group type: EXPERIMENTAL
Intervention: 2mg trihexyphenidyl
Number of subjects: 24
Study 20417063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18078614 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination DMARD therapy (sulfasalazine, methotrexate, hydroxychloroquine)
Number of subjects: 0
Study 18078614 — intervention group
Group type: EXPERIMENTAL
Intervention: Single DMARD therapy
Number of subjects: 0
Study 18078614 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-1beta levels
Number of subjects: 0
Study 18078614 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1beta levels at 0 months
Number of subjects: 0
Study 18078614 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1beta levels
Number of subjects: 0
Study 16107874 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity Restriction (AR)
Number of subjects: 73
Study 16107874 — intervention group
Group type: COMPARATOR
Intervention: No Activity Restriction (No AR)
Number of subjects: 73
Study 11865745 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality educational session (60 minutes)
Number of subjects: 39
Study 10522283 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping group (O)
Number of subjects: 40
Study 10522283 — intervention group
Group type: COMPARATOR
Intervention: Sequential group (S)
Number of subjects: 40
Study 8770718 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate antidepressant treatment (dosage not specified)
Number of subjects: 88